Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)

A ROCK inhibitor approved for treating vasospasms following subarachnoidal bleeding in Japan and China. Dosage: Participants will undergo a 2-week titration period at 60 mg daily before escalating to a maintenance dose of 120 mg daily.

Placebo tablets that look identical to the fasudil tablets and will follow the same dosing schedule as participants receiving fasudil.